Interview: Izana Tests GM-CSF Drug For Coronavirus

Compassionate Use Study Of Namilumab Starts In Italy

 
• By Kevin Grogan

The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.

Milan_Empty_Square
One of the trials for namilumab will be in Milan, a city hit hard by COVID-19 • Source: Shutterstock

More from COVID-19

More from Scrip